Bookmarks
WEiGht changes, caRdio-metabolic risks and mortality in patients with hypErThyroidism; all-cohort natural history and comparison of treatment effects in a CPRD-HES linked study. EGRET study
Safe People
University of Birmingham
Academic Institute
Barbara Torlinska - Chief Investigator - University of BirminghamBarbara Torlinska - Corresponding Applicant - University of BirminghamDaniel Lasserson - Collaborator - University of WarwickG. Neil Thomas - Collaborator - University of BirminghamJonathan Hazlehurst - Collaborator - University of BirminghamJulia Priestley - Collaborator - British Thyroid FoundationKeith Abrams - Collaborator - University of LeicesterKrishnarajah Nirantharakumar - Collaborator - University of BirminghamKristien Boelaert - Collaborator - University of BirminghamPhilip Saunders - Collaborator - NHS BIRMINGHAM AND SOLIHULL CCGSamuel Finnikin - Collaborator - University of Birmingham
Safe Projects
CPRD692
An overactive thyroid gland (hyperthyroidism) is common. Leaving the condition untreated can lead to serious health consequences as well as significant weight loss; however, treatment has been linked to additional weight gain, which is associated with increased risk of diabetes and heart disease.
The study aims to establish the natural history of weight changes in hyperthyroidism in any of the three treatment modalities, investigate the risk of obesity in regard to the treatment and compare these risks to the background population, and establish risks of cardio-metabolic conditions and death in each treatment modality. The data on patients diagnosed with hyperthyroidism between 01/01/1996 and 31/12/2015 will come from Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES) and ONS Death Registry.
08/03/2021
Safe Data
HES Admitted Patient Care
HES Outpatient
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Release